Subcutaneous sumatriptan,
does it really help with Pain freedom or relief within 15 minutes of an acute cluster headache attack?
research showsSubcutaneous sumatriptan 6 mg is rated C. Two randomized crossover trials produced large 15-minute pain responses, but evidence is concentrated in small Glaxo development trials and a completer analysis.
ads claimA rapid average response should not be expanded into guaranteed pain freedom for every attack. Daily injection limits and cardiovascular contraindications remain important.
Useful facts when choosing a product
- The index regimen was subcutaneous sumatriptan 6 mg early in an attack.
- The distinction is 49 randomized versus a paired analysis centered on the 39 who completed both periods.
Chamgap Semantic Classification Code
Candidate index · review held
M.sumatriptan.subcutaneous.pain-freedom-or-relief-within-of-an-acute-cluster-headache-attack.relieve.placeboMedicinal interventions > Sumatriptan > Subcutaneous > Pain freedom or relief within of an acute cluster headache attack > Symptom-relief claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The 1991 trial randomized 49 people but used a paired analysis centered on 39 who completed both periods. Pain freedom at 15 minutes was 46% versus 10%. Cochrane pooled results were about 48% versus 17% for 15-minute pain freedom and 75% versus 32% for pain relief. The included subcutaneous sumatriptan trials were Glaxo development studies, and no nonmanufacturer-funded trial was identified. Independent synthesis combines results but does not change source-trial funding.
Why this is classified as C (54)
Rapid pain benefit was large, but the 49-person trial, paired analysis centered on 39 completers, and absence of a nonmanufacturer-funded trial yield C with 54 points.
Counterpoint. Efficacy is rapid and clear, but evidence independence and analysis completeness limit the grade.
Rejudgment record. Cross-check applied — Accepted a large rapid pain effect while accounting for manufacturer development trials, small size, and completer-centered paired analysis
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R2 | Independently replicated across trials |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| No more than mild pain within 15 minutes | C | The index trial found 74% versus 26%. |
| Pain freedom within 15 minutes | C | The index trial found 46% versus 10%, with a positive Cochrane synthesis. |
| Reduced need for rescue oxygen | C | Rescue oxygen at 15 minutes was 13% versus 49% in the index trial. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Sumatriptan Cluster Headache Study Group. 1991 | Randomized double-blind placebo-controlled crossover trial | 49 randomized; 39 in the paired completer primary analysis | Glaxo Group Research development program; company investigators coauthored and generated the randomization code | Primary endpoint of no more than mild pain within 15 minutes | 74% versus 26%, P<0.001; pain freedom 46% versus 10%; primary endpoint succeeded | Direct efficacy with small completer analysis |
| Ekbom K et al. 1993 | Multicenter randomized double-blind placebo-controlled dose-comparison crossover trial | 134 randomized; 131 analyzed for the 6-mg outcome in the Cochrane extraction | Manufacturer development program with Glaxo Group Research employee coauthors | Headache relief at 15 minutes | 75% with 6 mg, 80% with 12 mg, and 35% with placebo; P<0.001 for each comparison; primary comparison succeeded | Replication within the same manufacturer program |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Subcutaneous sumatriptan x 15-minute relief of acute cluster headache — Evidence Grade C·54. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/subcutaneous-sumatriptan-acute-cluster-headache-15-minute-relief/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.